nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.01.2011 | Original Article

Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET

verfasst von: Tetsuya Tsujikawa, Yoshio Yoshida, Yasushi Kiyono, Tetsuji Kurokawa, Takashi Kudo, Yasuhisa Fujibayashi, Fumikazu Kotsuji, Hidehiko Okazawa

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the correlation between uptake of 16α-[¹⁸F]fluoro-17β-oestradiol (FES) and expression of oestrogen receptors as well as other related immunohistochemistry markers, positron emission tomography (PET) was performed in patients with endometrial carcinoma before surgery.

Methods

Nineteen patients with endometrioid adenocarcinoma underwent preoperative PET studies with FES and 2-[¹⁸F]fluoro-2-deoxy-D-glucose (FDG). Standardized uptake values (SUVs) for each tracer and the regional FDG to FES SUV ratio were calculated using images after coregistration. PET values were compared with postoperative stage, differentiation grade and immunohistochemical scores including oestrogen receptor subtypes (ERα, ERβ), progesterone receptor B (PR-B), Ki-67 and glucose transporter 1 (GLUT1).

Results

FES uptake showed a significantly positive correlation with expression of ERα. The FDG to FES ratio showed a significantly negative correlation with expression of ERα and PR-B. The FES uptake and FDG to FES ratio did not correlate with expression of ERβ, Ki-67 or GLUT1. FDG uptake was not correlated with any of the immunohistochemical scores. The PR-B score was strongly correlated with the ERα score. Well-differentiated carcinoma (grade 1) showed a significantly higher FES uptake and significantly lower FDG to FES ratio than moderately or poorly differentiated carcinoma (grade 2–3). None of the PET parameters were significantly different between advanced-stage carcinoma (≥ stage IB) and early-stage carcinoma (IA) based on the Féderation International de Gynécologie et d’Obstétrique (FIGO) staging classification. Differentiation grade was the most closely correlated parameter to FES uptake and FDG to FES ratio by multivariate analyses.

Conclusion

FES PET combined with FDG would be useful for non-invasive evaluation of ERα distribution, as well as ERα function, which reflects differentiation grade in endometrial carcinoma.

Utaaker E, Iversen OE, Skaarland E. The distribution and prognostic implications of steroid receptors in endometrial carcinomas. Gynecol Oncol 1987;28:89–100.CrossRefPubMed

Danforth Jr DN. Hormone receptors in malignancy. Crit Rev Oncol Hematol 1992;12:91–149.CrossRefPubMed

Gustafsson JA. Estrogen receptor β – a new dimension in estrogen mechanism of action. J Endocrinol 1999;163:379–83.CrossRefPubMed

Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, et al. The complete primary structure of human estrogen receptor beta (hER β) and its heterodimerization with ER α in vivo and in vitro. Biochem Biophys Res Commun 1998;243:122–6.CrossRefPubMed

Jongen V, Briët J, de Jong R, ten Hoor K, Boezen M, van der Zee A, et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 2009;112:537–42.CrossRefPubMed

Pertschuk LP, Masood S, Simone J, Feldman JG, Fruchter RG, Axiotis CA, et al. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol 1996;63:28–33.CrossRefPubMed

Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993;71:1467–70.PubMed

Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2007;106:325–33.CrossRefPubMed

McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, et al. Positron tomographic assessment of 16α-[¹⁸F]fluoro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32:1526–31.PubMed

10.

Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;36:1766–74.PubMed

11.

Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26:51–6.CrossRefPubMed

12.

Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006;24:2793–9.CrossRefPubMed

13.

Tsujikawa T, Yoshida Y, Mori T, Kurokawa T, Fujibayashi Y, Kotsuji F, et al. Uterine tumors: pathophysiologic imaging with 16α-[¹⁸F]fluoro-17β-estradiol and ¹⁸F fluorodeoxyglucose PET–initial experience. Radiology 2008;248:599–605.CrossRefPubMed

14.

Tsujikawa T, Yoshida Y, Kudo T, Kiyono Y, Kurokawa T, Kobayashi M, et al. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with ¹⁸F-FDG PET. J Nucl Med 2009;50:1598–604.CrossRefPubMed

15.

Yoo J, Dence CS, Sharp TL, Katzenellenbogen JA, Welch MJ. Synthesis of an estrogen receptor β-selective radioligand: 5-[¹⁸F]fluoro-(2R*,3S*)-2,3-bis(4-hydroxyphehyl)pentanenitrile and comparison of in vivo distribution with 16α-[¹⁸F]fluoro-17β-estradiol. J Med Chem 2005;48:6366–78.CrossRefPubMed

16.

Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103–4.CrossRefPubMed

17.

Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 1984;25:1212–21.PubMed

18.

Mori T, Kasamatsu S, Mosdzianowski C, Welch MJ, Yonekura Y, Fujibayashi Y. Automatic synthesis of 16α-[¹⁸F]fluoro-17β-estradiol using a cassette-type [¹⁸F]fluorodeoxyglucose synthesizer. Nucl Med Biol 2006;33:281–6.CrossRefPubMed

19.

Mylonas I, Jeschke U, Shabani N, Kuhn C, Kunze S, Dian D, et al. Steroid receptors ERα, ERβ, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. Histol Histopathol 2007;22:169–76.PubMed

20.

Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, et al. Prognostic significance of oestrogen receptor alpha (ERα) and beta (ERβ), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 2007;43:2434–44.CrossRefPubMed

21.

Conneely OM, Lydon JP, De Mayo F, O’Malley BW. Reproductive functions of the progesterone receptor. J Soc Gynecol Investig 2000;7:S25–32.CrossRefPubMed

22.

Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998;69:220–5.CrossRefPubMed

23.

Rose PG. Endometrial carcinoma. N Engl J Med 1996;335:640–9.CrossRefPubMed

24.

Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990;9:1603–14.PubMed

25.

Gronemeyer H. Transcription activation by estrogen and progesterone receptors. Annu Rev Genet 1991;25:89–123.CrossRefPubMed

26.

Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 2008;112:995–1000.CrossRefPubMed

27.

Peterson LM, Mankoff DA, Lawton T, Yagle K, Schubert EK, Stekhova S, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and ¹⁸F-fluoroestradiol. J Nucl Med 2008;49:367–74.CrossRefPubMed

28.

Mankoff DA, Dehdashti F. Imaging tumor phenotype: 1 plus 1 is more than 2. J Nucl Med 2009;50:1567–9.CrossRefPubMed

29.

Behrooz A, Ismail-Beigi F. Stimulation of glucose transport by hypoxia: signals and mechanisms. News Physiol Sci 1999;14:105–10.PubMed

30.

Stoner M, Saville B, Wormke M, Dean D, Burghardt R, Safe S. Hypoxia induces proteasome-dependent degradation of estrogen receptor α in ZR-75 breast cancer cells. Mol Endocrinol 2002;16:2231–42.CrossRefPubMed

31.

Cooper C, Liu GY, Niu YL, Santos S, Murphy LC, Watson PH. Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor α in human breast carcinoma. Clin Cancer Res 2004;10:8720–7.CrossRefPubMed

32.

Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, et al. ¹⁸F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004;45:22–9.PubMed

33.

Helin ML, Helle MJ, Helin HJ, Isola JJ. Proliferative activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of 102 breast carcinomas. Arch Pathol Lab Med 1989;113:854–7.PubMed

34.

Sirvent JJ, Santafé M, Salvadó MT, Alvaro T, Raventós A, Palacios J. Hormonal receptors, cell proliferation fraction (Ki-67) and c-erbB-2 amplification in breast cancer. Relationship between differentiation degree and axillary lymph node metastases. Histol Histopathol 1994;9:563–70.PubMed

35.

Gaffney EV, Venz-Williamson TL, Hutchinson G, Biggs PJ, Nelson KM. Relationship of standardized mitotic indices to other prognostic factors in breast cancer. Arch Pathol Lab Med 1996;120:473–7.PubMed

36.

Takama F, Kanuma T, Wang D, Kagami I, Mizunuma H. Oestrogen receptor β expression and depth of myometrial invasion in human endometrial cancer. Br J Cancer 2001;84:545–9.CrossRefPubMed

37.

Fujimoto J, Sakaguchi H, Aoki I, Toyoki H, Tamaya T. Clinical implications of the expression of estrogen receptor-α and -β in primary and metastatic lesions of uterine endometrial cancers. Oncology 2002;62:269–77.CrossRefPubMed

Titel: Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[18F]fluoro-17β-oestradiol PET
verfasst von: Tetsuya Tsujikawa
Yoshio Yoshida
Yasushi Kiyono
Tetsuji Kurokawa
Takashi Kudo
Yasuhisa Fujibayashi
Fumikazu Kotsuji
Hidehiko Okazawa
Publikationsdatum: 01.01.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2011
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1589-8

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Erratum to: Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology

EJNMMI Research: a new journal in nuclear medicine

Oops ... we did it again!

Book review: S. Mirzaei and M. Schenk (eds) Abbilder der Folter

Clinical audit in nuclear medicine

PET/CT in paediatric oncology: clinical usefulness and dosimetric concerns